Literature DB >> 28674474

Heart Failure: A Class Review of Pharmacotherapy.

Ami Shah, Dimple Gandhi, Sneha Srivastava, Kunal J Shah, Rupal Mansukhani.   

Abstract

A recent guideline update for the treatment of heart failure has created the need for a new look at the medication classes and trials related to the disease. The authors focus on pharmacological options available for treating the problem.

Entities:  

Year:  2017        PMID： 28674474      PMCID： PMC5481297     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  42 in total

Review 1.  Balancing diuretic therapy in heart failure: loop diuretics, thiazides, and aldosterone antagonists.

Authors:  Sara Paul
Journal:  Congest Heart Fail       Date:  2002 Nov-Dec

2.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

3.  2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake
Journal:  Circulation       Date:  2016-05-20       Impact factor: 29.690

4.  Thiazide-sensitive sodium chloride cotransport in early distal tubule.

Authors:  D H Ellison; H Velázquez; F S Wright
Journal:  Am J Physiol       Date:  1987-09

5.  Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.

Authors:  Karl Swedberg; Michel Komajda; Michael Böhm; Jeffrey Borer; Michele Robertson; Luigi Tavazzi; Ian Ford
Journal:  J Am Coll Cardiol       Date:  2012-05-29       Impact factor: 24.094

6.  Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.

Authors:  R Rocha; P N Chander; K Khanna; A Zuckerman; C T Stier
Journal:  Hypertension       Date:  1998-01       Impact factor: 10.190

7.  Chronic administration of aldosterone depresses baroreceptor reflex function in the dog.

Authors:  W Wang
Journal:  Hypertension       Date:  1994-11       Impact factor: 10.190

8.  Lifetime risk for heart failure among white and black Americans: cardiovascular lifetime risk pooling project.

Authors:  Mark D Huffman; Jarett D Berry; Hongyan Ning; Alan R Dyer; Daniel B Garside; Xuan Cai; Martha L Daviglus; Donald M Lloyd-Jones
Journal:  J Am Coll Cardiol       Date:  2013-04-09       Impact factor: 24.094

Review 9.  Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system.

Authors:  K T Weber; C G Brilla
Journal:  Circulation       Date:  1991-06       Impact factor: 29.690

10.  Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.

Authors:  Kim Fox; Ian Ford; P Gabriel Steg; Michal Tendera; Roberto Ferrari
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321
View more
  8 in total

1.  Echocardiographic changes in elderly patients with heart failure with reduced ejection fraction after sacubitril-valsartan treatment.

Authors:  Wei Gu; Chuangye Xu; Zhao Li; Zhi-Zhong Li
Journal:  Cardiovasc Diagn Ther       Date:  2021-10

Review 2.  The Atrium in Atrial Fibrillation - A Clinical Review on How to Manage Atrial Fibrotic Substrates.

Authors:  Pedro Silva Cunha; Sérgio Laranjo; Jordi Heijman; Mário Martins Oliveira
Journal:  Front Cardiovasc Med       Date:  2022-07-04

3.  Adjuvant testosterone therapy in chronic heart failure (ATTIC): a randomised open-label trial.

Authors:  Minakshi Dhar; Kartik Mittal; Ashwin Parchani; Manu Sharma; Yogesh Bahurupi; Sanjay Kalra; Nowneet Kumar Bhat
Journal:  BMJ Open       Date:  2022-05-31       Impact factor: 3.006

Review 4.  Cardiac amyloidosis-A review of current literature for the practicing physician.

Authors:  Samantha Ash; Eran Shorer; Devyani Ramgobin; Maique Vo; Jonathan Gibbons; Reshma Golamari; Rahul Jain; Rohit Jain
Journal:  Clin Cardiol       Date:  2021-02-17       Impact factor: 3.287

Review 5.  Milestones in Heart Failure: How Far We Have Come and How Far We Have Left to Go.

Authors:  Harini Gajjela; Iljena Kela; Chandra L Kakarala; Mohammad Hassan; Rishab Belavadi; Sri Vallabh Reddy Gudigopuram; Ciri C Raguthu; Srimy Modi; Ibrahim Sange
Journal:  Cureus       Date:  2021-12-12

6.  Polypharmacy among older individuals with heart failure: trends between 2000 and 2017 in the province of Quebec, Canada.

Authors:  Alexandre Campeau Calfat; Marc Simard; Amina Ouali; Claudia Blais; Caroline Sirois
Journal:  Ther Adv Cardiovasc Dis       Date:  2022 Jan-Dec

Review 7.  New Strategies to Prevent Rehospitalizations for Heart Failure.

Authors:  Jamie Diamond; Adam D DeVore
Journal:  Curr Treat Options Cardiovasc Med       Date:  2022-09-22

8.  Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors.

Authors:  Marc Evans; Angharad R Morgan; Zaheer Yousef; Gethin Ellis; Umesh Dashora; Dipesh C Patel; Pam Brown; Wasim Hanif; Johnathan N Townend; Naresh Kanumilli; Jim Moore; John P H Wilding; Stephen C Bain
Journal:  Drugs       Date:  2021-06-23       Impact factor: 9.546
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.